Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Proceedings Of NIAID Workshop On Immunity To Malaria Published
Researchers have made progress in developing malaria vaccines over the past few decades, but the goal remains a daunting challenge. Malaria has evolved to thwart almost every aspect of the human immune system. On March 16-17, 2009, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, convened a workshop to encourage more immunologists to enter malaria research and to foster scientific collaborations that may help lead to the development of effective malaria vaccines. The proceedings of that meeting are in the July 2009 issue of Nature Immunology, and available online June 18.
generic viagra online
Eating Curry Every Week 'could Prevent Dementia'
Eating a curry once or twice a week could help prevent the onset of Alzheimer"s disease and dementia. The magic ingredient in curry is curcumin, a component of the spice, turmeric.
News of the day
Programs Bring Innovation To Palliative And End-of-Life Care
Three programs that expand the reach of palliative and end-of-life care will be recognized as the 2009 recipients of the Circle of Life Award®: Celebrating Innovation in End-of-Life Care, along with two others that were awarded citations of honor.
Medical Devices

Medarex To Receive Milestone Payment For The Approval Of Ilaris For The Treatment Of Cryopyrin-Associated Periodic Syndrome

Medarex, Inc. (NASDAQ:MEDX) announced it will receive a milestone payment of an undisclosed amount from Novartis Pharma AG (Novartis), in connection with the marketing approval from the U.S. Food and Drug Administration (FDA), to market Ilaris® (canakinumab, previously known as ACZ885) for the treatment of children as young as four years old and adults with cryopyrin-associated periodic syndrome, or CAPS, a serious life-long auto-inflammatory disease caused by rare genetic mutations. CAPS comprises three disorders of increasing severity: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID). A clinical study is ongoing to evaluate the potential of Ilaris® to treat patients with NOMID. In addition to ongoing studies in CAPS, clinical trials are also under way with Ilaris® in systemic juvenile idiopathic arthritis (SJIA), and more common disorders such as some forms of gout, chronic obstructive pulmonary disorder (COPD) and type 2 diabetes. Ilaris® is a fully human monoclonal antibody generated using Medarex"s UltiMAb® technology that rapidly and selectively blocks interleukin-1 beta (IL-1í²). Regulatory applications have also been filed in Europe, Switzerland, Australia and other countries. Under the agreement with Novartis, Medarex will receive future sales-based royalty payments from the commercial sales of Ilaris®. "Ilaris® represents the third antibody generated from our UltiMAb® technology to receive regulatory approval and reinforces the important role of our antibody technology platform in developing new treatment options for unmet medical needs," said Howard H. Pien, Chairman and CEO of Medarex. "The royalty stream generated from future product sales will provide valuable financial support to advancing our own maturing product pipeline toward commercialization." Medarex, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009